The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...

Shares of BioArctic AB tumbled by 7% on Friday following news that the European Commission (EC) has requested further review of the company's Alzheimer's drug, lecanemab, by the Committee for ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

He leads on our fundraising for our strategic priorities such as our Drug Discovery Alliance ... Peter has extensive experience in philanthropy and joined Alzheimer’s Research UK having established a ...

Could changes in cholesterol be a warning sign of dementia? A new study suggests that older adults whose cholesterol ...

Older adults whose cholesterol changes over time may be more likely to develop dementia than people whose cholesterol is ...

Two new PET radiotracers have outperformed the only current Food and Drug Administration (FDA) approved radiotracer for ...

In this week’s edition of InnovationRx, we look at HHS nominee Robert F. Kennedy Jr.’s first Senate confirmation hearing, the ...

President Donald Trump signed the bipartisan Laken Riley Act into law as his administration’s first piece of legislation.